SNPHY - Santen's dry eye therapy Cationorm gets approval in Canada

• Santen Pharmaceutical's ( OTCPK:SNPHY ) ( OTCPK:SNPHF ) unit Santen Canada received Health Canada's approval of Cationorm Plus for relief of dry eye and ocular allergy symptoms.
• Cationorm Plus is a sterile, preservative-free, artificial tear containing a novel technology called Novasorb, the company said in an Oct. 6 press release.
• "We are pleased that with this approval, doctors and patients in Canada will now benefit from the first artificial tear that uses a positive cationic emulsion to provide improved hydration in the eye," said Craig Wallace, general manager of Canada, U.K., Ireland, and South Africa at Santen.

For further details see: